Clinical Trial Update: Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of Onvansertib in combination with gemcitabine and nab-paclitaxel for locally advanced, unresectable, or metastatic pancreatic ductal adenocarcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Onvansertib (onvansertib)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: WITHDRAWN